23-valent pneumococcal polysaccharide vaccine
- Generic Name
- 23-valent pneumococcal polysaccharide vaccine
The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23
Phase 1
Completed
- Conditions
- Healthy Controls
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 33
- Registration Number
- NCT02097589
- Locations
- 🇺🇸
University of Florida Clinical Translational Research Building, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath